Neuralstem, Inc. is focused on developing and commercializing of treatments for central nervous system disease based on transplanting human neural stem cells and small molecule drugs. The Company has developed and maintain a portfolio of patents and patent applications that form the base of its research and development efforts in the areas of neural stem cell research, small molecule research, and related technologies.
04/10/11Neuralstem shares jump over 13% on new stem cell patent
16/12/10Neuralstem Receives FDA Approval to Start Phase Ia Trial for Depression Drug
14/09/10Study Shows Neuralstem’s Stem Cells May Have Application To Treating Stroke
Recent Sector News
U.S. stock-index futures were lower today as the equities market reopens after the Thanksgiving holiday. Energy producers tumbled and airlines stocks advanced after OPEC’s decision to maintain its production target. Futures for the Dow Jones Industrial Average and those for the S&P 500 index each lost 0.2. The Nasdaq 100 index rose 0.1 percent. Wall Street was closed for the U.S. Thanksgiving holiday yesterday and will shut three hours earlier today.
Nanobiotix has agreed a significant funding deal with a US investor that will broaden the scope of development of its ground-breaking advance on traditional radiotherapy.
U.S. stocks edged up amid thin volumes Wednesday after a deluge of data, including a spike in initial jobless claims, a jump in durable goods and lower-than-anticipated consumer spending and new home sales. Both the S&P 500 and the Dow managed to clinch new records.
Epizyme (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers, had its “buy” rating and $45 price target reaffirmed at H.C. Wainwright, which cited “strong accrual” of objective responses in the dose-escalation study of its EZH2 inhibitor (EPZ-6438).
Matica Enterprises (CSE:GRF) surged 50 percent on Friday after its stock resumed trading on the Canadian Securities Exchange, following a definitive agreement to acquire a Novia Scotia medical marijuana growing facility with "ready to build" status under the new Canadian regime.
Aeterna Zentaris (NASDAQ:EZS) (TSE:AEZ) shares plunged Thursday by more than 45 percent after the company received a complete response letter from the FDA for its Macrilen experimental test, with the regulatory body citing several problems, including a serious adverse event.
Investors interested in Neuralstem recently viewed
- Medgenics (AMEX , AIM: MDGN) Developing "Biopump" technology for the treatment of chronic diseases
- Supreme Pharmaceuticals (CSE: SL) Targeting opportunities in the medical marijuana and obesity sectors
- Admedus (ASX: AHZ) Making a difference in Healthcare
- Stirling Products (ASX: STI) Your well-being is our priority
- Advanced Oncotherapy (AIM: AVO) New technology for innovative and patient-focused cancer treatments